What to Know About Medicare's Hemp-Derived Product Program
The Centers for Medicare and Medicaid Services (CMS) launched a pilot program in April to allow certain Medicare enrollees access to hemp-derived products. The program allows participating organizations to furnish eligible hemp-derived products for up to $500 per year per eligible beneficiary.
The Centers for Medicare and Medicaid Services (CMS) launched a pilot program to allow certain Medicare enrollees access to hemp-derived products. Eligible products can be incorporated into patient care plans under clinician guidance. The program is available to beneficiaries enrolled in the Accountable Care Organization Realizing Equity, Access, and Community Health (ACO REACH) model and the Enhancing Oncology Model. Five ACO REACH organizations have submitted implementation plans, which CMS will review. Eligible hemp-derived products must contain no more than 0.3% delta-9 tetrahydrocannabinol (THC). Participating organizations are responsible for procurement and must comply with program integrity safeguards.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.